Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LADAVRU
- Development stage
- Preclinical
- Lead developer
- Hoverink Biotechnologies
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
LADAVRU is an investigational small molecule drug candidate being developed by Hoverink Biotechnologies as a proprietary opioid alternative. It is a formulation of dronabinol, a synthetic cannabinoid, combined with citric acid and mannitol, designed for delivery as an intravenous injection or a solid preparation. The drug is currently in pre-clinical development for the treatment of chronic pain, neuropathy, and nausea and discomfort associated with chemotherapy. It is also being explored for broader applications in conditions such as cancer, cirrhosis, cirrhosis ascites, AIDS, and specifically for relapsed or refractory acute myeloid leukemia (AML) in patients treated with anthracyclines.
- Brand names
- LADAVRU
Beyond the preview
Go deeper on LADAVRU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LADAVRU.